Prescribing overview
Galliprant controls canine osteoarthritis pain and inflammation through EP4 antagonism rather than COX inhibition. Its distinct mechanism does not eliminate adverse effects or monitoring requirements.
Key prescribing checks
- Assess pre-existing illness and establish regular monitoring. Prior analgesic reactions, dehydration and concurrent medications are relevant parts of the patient history.
- Avoid concurrent NSAIDs or corticosteroids unless a veterinarian has resolved the label’s warnings and selected a specific plan. It is not an automatic add-on to another anti-inflammatory.
- Known grapiprant hypersensitivity is a contraindication. Reduced appetite, vomiting, diarrhea or other suspected adverse signs require prompt prescriber assessment.
- Canine labeling does not establish safety in another species or eligibility for every age or body size.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
FDA-approved Galliprant indicationOsteoarthritis pain/inflammation
Canine oral tablets only.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Blocks the prostaglandin E2 EP4 receptor without inhibiting cyclooxygenase.
Absorption, distribution, metabolism and elimination
Healthy Beagles: terminal half-life 4.60–5.67 hours; food reduces exposure. Canine plasma binding approximately 95%.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Galliprant
U.S. canine oral-tablet label.
Contraindications · when not to use
- Grapiprant hypersensitivity.
Precautions & monitoring
- Review dehydration, kidney/cardiac/liver disease and reproductive/young-patient evaluation limits.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Vomiting, diarrhea and inappetence; renal, hepatic and gastrointestinal adverse events require attention.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| Dogs ≥9 months, ≥8 lb (3.6 kg)Osteoarthritis pain/inflammationGalliprant tablets | 2 mg/kg (0.9 mg/lb) Oral · Once daily Lowest effective dose, shortest duration consistent with response | Calculate half-tablet increments; only 20/60 mg tablets scored. Do not split 100 mg tablets; >150 lb requires combinations. Verify full dosing label ↗ |
Safety below 9 months is unestablished.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Galliprant
U.S. canine oral-tablet label.
- Do not combine with oral/injectable NSAIDs or corticosteroids; plan washouts and review nephrotoxic medicines.
Monitoring
Baseline/periodic blood counts and chemistry; review hydration and comorbidity.
Client counseling
Do not combine with other oral/injectable NSAIDs or corticosteroids; report intolerance.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Store at or below 30°C, inaccessible to pets.
Brands, formulations & ingredient identity
Active ingredients
grapiprant
Galliprant identifies grapiprant, not gabapentin. Similar spelling should not replace an ingredient check during dispensing.
It has a different mechanism from COX-inhibiting NSAIDs, but that distinction does not mean it is free of gastrointestinal, renal or hepatic concerns.
The tablet strengths have different scoring features. Verify the actual tablet and full prescribing instructions before dividing it or selecting a strength.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Galliprant
- Formulation
- Flavored oral tablets
- Label / product scope
- Dogs
Canine osteoarthritis product; EP4 antagonist NSAID.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →